Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes
Richard WA Mackenzie, Bradley T Elliott Department of Human and Health Sciences, Facility of Science and Technology, University of Westminster, London, UK Abstract: Type 2 diabetes is a metabolic disease categorized primarily by reduced insulin sensitivity, β-cell dysfunction, and elevate...
Enregistré dans:
Auteurs principaux: | Mackenzie RWA, Elliott BT |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b73ae4b8d3e54629a513d7ca40a4e922 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Insulin detemir for the treatment of obese patients with type 2 diabetes
par: Hollander PA
Publié: (2012) -
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
par: Stanley S Schwartz
Publié: (2010) -
Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage [Corrigendum]
par: Wilke T, et autres
Publié: (2019) -
Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
par: Paul Valensi
Publié: (2009) -
Insulin glulisine in the management of diabetes
par: Satoru Yamada
Publié: (2009)